United Kingdom and Ireland

In the UK*, our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services.

Alexion’s UK office was one of the first affiliates to open outside of the US, in 2006, to serve patients across the UK and also Ireland. The UK has a rich heritage in rare disease clinical research, and Alexion is proud of our collaborations and partnerships. For example, the UK’s paroxysmal nocturnal haemoglobinuria (PNH) clinical community and Alexion UK spent many years collaborating to identify and research therapies for the disease. Alexion UK is also a strong partner to the healthcare community offering a number of educational programs, and is a member of the Genomics England’s Discovery Forum; 100,000 Genomes Project to help improve earlier diagnosis for patients with life-threatening kidney and neurological diseases.   

In the UK and Ireland, we work across various rare diseases and devastating conditions, including:

  • Paroxysmal Nocturnal Haemoglobinuria (PNH) – a progressive condition involving thrombosis & end-organ damage
  • Atypical Haemolytic Uraemic Syndrome (aHUS) – a potentially fatal thrombotic microangiopathy
  • Paediatric Onset Hypophosphatasia (HPP) – a metabolic disease with multiple systemic, morbid manifestations
  • Lysosomal Acid Lipase Deficiency (LAL-D) – a disease of progressive multi-organ damage and premature death
  • Neurofibromatosis type 1 (NF1) - a genetic condition that causes tumours to grow along nerves. The tumours are usually non-cancerous (benign).

Transparency & Disclosure

Alexion is committed to operating with integrity, accountability, and transparency, and to complying with all applicable laws and regulations. Alexion fully participates in the Association of British Pharmaceutical Industry’s (ABPI) Disclosure UK initiative to increase transparency about the relationships we have with doctors, nurses, pharmacists, and other healthcare professionals. Further information on disclosure can be found here.

Working with Patient Groups

People living with rare and devastating diseases are our inspiration and our Guiding Star. Every day we strive to live up to their expectations by following our culture values to put patients first, do the right thing, follow the science, be entrepreneurial, and play to win.

Alexion respects the independence and integrity of patient organisations. We declare any support provided to patient groups to ensure transparency of our partnerships.

View the contributions we have made to patient organisations:

Contributions to UK and Irish Patient Organisations & Methodological notes 2023

Contributions to UK and Irish Patient Organisations & Methodological notes 2022

Contributions to UK and Irish Patients Organisations 2015-2021

Working with Members of the Public

View the contributions we have made for certain contracted services paid to members of the UK Public, including patients and journalists.

Contributions to Members of the Public & Methodological Notes 2023

Contributions to Members of the Public & Methodological Notes 2022

Clinical Trials in the UK

Alexion works with clinicians and the wider healthcare community in the UK & Ireland to undertake carefully planned clinical studies designed to help deliver a better tomorrow for people living with rare diseases and devastating conditions.

We lead the way in rare disease clinical trial innovation by tailoring core elements of the clinical trial process to meet the unique needs of the rare disease patients we aim to serve. Our close ties to the rare disease community and our patient-centric approach to clinical trials are the keys to our success. Conducting clinical research in rare diseases is complex and challenging, and the risk of failure is high. Yet Alexion continues to innovate and evolve into new areas where there is great unmet need and an opportunity to help people fully live their best lives.

More information about Alexion clinical studies happening in the UK

Alexion conducts many clinical research programs in the UK and in 2019 invested £1.5 million into clinical research in the UK alone. Further information can be found herei.


Our people make a crucial contribution to creating a positive impact for patients and we are focusing on our employees’ experience, inclusive of our culture, to ensure we reach our ambition of becoming the #1 patient-centric organisation as well as the most rewarding company to work for.

Working at Alexion is an experience like no other. With a focus on rare diseases that have few, if any, effective treatments, each endeavour is urgent and every day counts. Ground-breaking innovation and life-changing therapies, driven by a team with a shared sense of purpose and dedication — that’s Alexion.



This webpage is intended for residents of the UK.

*Alexion UK encompasses all operations across the UK and Republic of Ireland commercial and Sales operations.

iRef – ABPI disclosures site